High hepatotoxicity rate seen among HAART patients.
Evidence continues to mount showing that HIV patients receiving antiretroviral treatment are at high risk for hepatotoxicity. The National Institutes of Health presented findings on liver toxicity among 10,011 HIV patients at the first International AIDS Society conference. The retrospective analysis shows that liver toxicity is associated with all classes of antiretroviral medications in use, and not just with regimens containing nevirapine or hydroxyurea, the two drugs about which the FDA recently issued hepatotoxicity warnings.
Reisler
K
K
D019380:Anti-HIV Agents / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D006801:Humans; D008099:Liver / Q000187:drug effects*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors